Table 1.

Summary of results for evaluation of multiplexed inflammation marker assays

Bio-Rad number of markers (%)Millipore number of markers (%)
Total67 (100.0)97 (100.0)
Markers with >25% detection
Serum56 (83.5)89 (91.7)
Heparin plasma63 (94.0)89 (91.7)
EDTA plasma64 (95.5)89 (91.7)
Markers with <20% CV for across-batch duplicatesa
Serum51 (76.2)75 (77.3)
Heparin plasma52 (77.6)69 (71.1)
EDTA plasma47 (70.1)78 (80.4)
ICCs for across-batch duplicates
Serum
 <0.506 (8.9)5 (5.1)
 0.50–0.8029 (43.3)32 (33.0)
 0.80–0.9012 (17.9)19 (19.5)
 >0.9011 (16.4)34 (35.1)
Heparin plasma
 <0.503 (4.5)9 (9.3)
 0.50–0.8038 (56.7)31 (31.9)
 0.80–0.9015 (22.3)25 (25.8)
 >0.907 (10.4)28 (28.9)
EDTA plasma
 <0.505 (7.5)7 (7.2)
 0.50–0.8049 (73.1)25 (25.8)
 0.80–0.905 (7.5)24 (24.7)
 >0.905 (7.5)37 (38.1)
Markers with acceptable performanceb45 (67.2)71 (73.2)
  • aCVs and ICCs were calculated for 20 blinded duplicate samples for each specimen type that were placed across different batches.

  • bAcceptable performance was defined as: (i) being detectable in greater than 25% of the 100 samples on all 3 specimen types and (ii) across-batch CVs of less than 20% for blinded duplicates on at least 2 of the 3 specimen types.